Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $782,880.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the transaction, the insider directly owned 32,718 shares in the company, valued at approximately $3,659,181.12. This represents a 17.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.28, for a total value of $550,568.16.

Oruka Therapeutics Stock Up 1.5%

Shares of Oruka Therapeutics stock traded up $1.62 during trading hours on Monday, reaching $112.66. 514,852 shares of the stock traded hands, compared to its average volume of 1,134,557. Oruka Therapeutics, Inc. has a one year low of $14.08 and a one year high of $113.04. The firm has a market capitalization of $7.46 billion, a price-to-earnings ratio of -55.50 and a beta of -0.34. The company has a 50 day moving average price of $87.52 and a 200 day moving average price of $62.81.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Algert Global LLC grew its position in shares of Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares in the last quarter. Royal Bank of Canada lifted its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares in the last quarter. AlphaCentric Advisors LLC boosted its stake in Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after purchasing an additional 626 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ORKA. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Barclays lifted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Finally, UBS Group boosted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.